Net prices of new antiobesity medications
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective: Glucagon‐like peptide‐1 receptor agonists (GLP1s) are effective antiobesity drugs and the subject of intense debate around insurance coverage due to the large prevalence of obesity and overweight. The estimation of the budget impact associated with GLP1 insurance coverage requires estimates of GLP1 prices that account for manufacturer discounts. The authors applied a peer‐reviewed method to estimate the net prices of GLP1s after manufacturer discounts. Methods: The authors estimated manufacturer discounts for each product as the difference between the gross sales estimated at list price and manufacturer‐reported revenue. From this difference, the authors subtracted discounts to government programs, including 340B, Medicaid, and the Medicare Part D coverage gap, and attributed the remaining amount to manufacturer discounts provided in the commercial market. Results: Manufacturer discounts for GLP1s approved for obesity were estimated at 41%, which translated into net prices of $717 to $761 per month of supply. Manufacturer discounts for GLP1s approved for type 2 diabetes ranged from 54% to 59%, which translated into net prices of $312 to $469 per month of supply. Conclusions: The magnitude of manufacturer discounts underscores the need to consider net price information in studies that inform private and public payers' decision‐making around coverage of GLP1s for obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“GLP1s are highly effective antiobesity agents [1, 2], and in recent trials, they were associated with significant reductions in the incidence of cardiovascular events [ 3].”
BackgroundSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“…a 20% reduction in the risk of major cardiovascular events in adults with overweight or obesity and a history of myocardial infarction, stroke, or peripheral arterial disease of the extremities and an improvement in heart failure-related symptoms in patients with obesity and heart failure [3, 17].”
BackgroundMedicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead
Baig, K., Dusetzina, S. B., Kim, D. D., & Leech, A. A. (2023) · New England Journal of Medicine · doi:10.1056/nejmp2300516 · Cited by 66 · cited 2×
“Specifically, arguments against insurance coverage of GLP1s have centered on their failure to meet commonly accepted cost-effectiveness thresholds and their expected budget impact at current prices [5, 6].”
BackgroundMedicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform
Hernandez, I., Wright, D. R., Guo, J., & Shrank, W. H. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08416-9 · Cited by 18
Self-citation
Cited by
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2024.5586 · Cited by 77
Discontinuation of glucagon-like peptide-1 receptor agonists.
Khan, S. S., Ndumele, C. E., & Kazi, D. S. (2025) · JAMA · doi:10.1001/jama.2024.22284 · Cited by 60
Factors Associated With Semaglutide Initiation Among Adults With Obesity
Podolsky, M. I., Raquib, R., Shafer, P. R., Hempstead, K., Ellis, R. P., & Stokes, A. C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.55222 · Cited by 26
Kim, D. D., Hwang, J. H., & Fendrick, A. M. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae055 · Cited by 21
Ippolito, B., & Levy, J. F. (2024) · Health Affairs · doi:10.1377/hlthaff.2024.00356 · Cited by 14
Metadata
- Authors
- Hernandez, I., & Sullivan, S. D.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2024-01-16
- Volume
- 32
- Issue
- 3
- Pages
- 472-475
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W4390928550
- Cited by
- 22
- References
- 4
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.